SCHEMBL15924451

SCHEMBL15924451

Cc1cccc(-c2nc3c(c(=O)[nH]c(=O)n3C)n2Cc2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
POLB P06746 2/20 0.58
TP53 P04637 3/20 0.52
HSD17B10 Q99714 2/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 5/20 0.52
TSHR P16473 4/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HPGD P15428 1/20 0.51
MDM2 Q00987 4/20 0.50
KDM4E B2RXH2 2/20 0.50
GAA P10253 1/20 0.49
KDM1A O60341 1/20 0.49
IDO1 P14902 1/20 0.49
SIRT5 Q9NXA8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15924151 0.87 TP53 (0.51) KMT2AMEN1POLBTP53HSD17B10
SCHEMBL15923850 0.79 GAA (0.56) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL15924216 0.79 MEN1 (0.55) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL15923656 0.75 KMT2A (0.53) KMT2AMEN1POLBTP53HSD17B10
SCHEMBL16028612 0.73 TRPC4 (0.54) KMT2AMEN1POLBTP53HSD17B10
SCHEMBL17845823 0.72 KDM4E (0.56) KMT2AMEN1POLBHTTALDH1A1
SCHEMBL15922037 0.72 MDM2 (0.58) MDM2
SCHEMBL20105786 0.72 GAA (0.50) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL15923584 0.71 ATM (0.46) KMT2AMEN1POLBTP53HSD17B10
SCHEMBL27411452 0.71 ALDH1A1 (0.67) KMT2AMEN1POLBTP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2951180-B1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME (US) 2018-05-02 EP disclosed
US-9540377-B2 2,6,7,8 substituted purines as HDM2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-01-10 US disclosed
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-10 US disclosed
EP-2951180-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-12-09 EP disclosed
WO-2014120748-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS DDX21, DPYD, NSUN2 KMT2A 258/4885MEN1 2986/4885POLB 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.